199 related articles for article (PubMed ID: 24841929)
1. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
[TBL] [Abstract][Full Text] [Related]
2. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
[TBL] [Abstract][Full Text] [Related]
3. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M
World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310
[TBL] [Abstract][Full Text] [Related]
4. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
Taneja SS; Bennett J; Coleman J; Grubb R; Andriole G; Reiter RE; Marks L; Azzouzi AR; Emberton M
J Urol; 2016 Oct; 196(4):1096-104. PubMed ID: 27291652
[TBL] [Abstract][Full Text] [Related]
5. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
[TBL] [Abstract][Full Text] [Related]
6. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.
Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M
J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311
[TBL] [Abstract][Full Text] [Related]
8. Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.
Betrouni N; Boukris S; Benzaghou F
Lasers Med Sci; 2017 Aug; 32(6):1301-1307. PubMed ID: 28569345
[TBL] [Abstract][Full Text] [Related]
9. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
Trachtenberg J; Bogaards A; Weersink RA; Haider MA; Evans A; McCluskey SA; Scherz A; Gertner MR; Yue C; Appu S; Aprikian A; Savard J; Wilson BC; Elhilali M
J Urol; 2007 Nov; 178(5):1974-9; discussion 1979. PubMed ID: 17869307
[TBL] [Abstract][Full Text] [Related]
10. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.
Azzouzi AR; Lebdai S; Benzaghou F; Stief C
World J Urol; 2015 Jul; 33(7):937-44. PubMed ID: 25786708
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].
Lebdai S; Martin F; Bigot P; Azzouzi AR
Prog Urol; 2014 Nov; 24(14):911-4. PubMed ID: 25195031
[TBL] [Abstract][Full Text] [Related]
12. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.
Betrouni N; Lopes R; Puech P; Colin P; Mordon S
Phys Med Biol; 2011 Aug; 56(15):4771-83. PubMed ID: 21753234
[TBL] [Abstract][Full Text] [Related]
13. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
Eymerit-Morin C; Zidane M; Lebdai S; Triau S; Azzouzi AR; Rousselet MC
Virchows Arch; 2013 Oct; 463(4):547-52. PubMed ID: 23948957
[TBL] [Abstract][Full Text] [Related]
14. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.
Chelly S; Maulaz P; Bigot P; Azzouzi AR; Lebdai S
Asian J Androl; 2020; 22(5):454-458. PubMed ID: 31939351
[TBL] [Abstract][Full Text] [Related]
15. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Azzouzi AR; Vincendeau S; Barret E; Cicco A; Kleinclauss F; van der Poel HG; Stief CG; Rassweiler J; Salomon G; Solsona E; Alcaraz A; Tammela TT; Rosario DJ; Gomez-Veiga F; Ahlgren G; Benzaghou F; Gaillac B; Amzal B; Debruyne FM; Fromont G; Gratzke C; Emberton M;
Lancet Oncol; 2017 Feb; 18(2):181-191. PubMed ID: 28007457
[TBL] [Abstract][Full Text] [Related]
16. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.
Davidson SR; Weersink RA; Haider MA; Gertner MR; Bogaards A; Giewercer D; Scherz A; Sherar MD; Elhilali M; Chin JL; Trachtenberg J; Wilson BC
Phys Med Biol; 2009 Apr; 54(8):2293-313. PubMed ID: 19305043
[TBL] [Abstract][Full Text] [Related]
17. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.
Rodriguez-Rivera JA; Rodriguez-Lay R; Zegarra-Montes L; Benzaghou F; Gaillac B; Azzouzi AR; Reis LO; Palma P
Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):632-638. PubMed ID: 29699883
[TBL] [Abstract][Full Text] [Related]
18. Re: TOOKAD® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Cadeddu JA
J Urol; 2014 May; 191(5):1290. PubMed ID: 24745491
[No Abstract] [Full Text] [Related]
19. Re: TOOKAD ® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Taneja SS
J Urol; 2014 Apr; 191(4):983-4. PubMed ID: 24703118
[No Abstract] [Full Text] [Related]
20. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.
Lebdai S; Villers A; Barret E; Nedelcu C; Bigot P; Azzouzi AR
World J Urol; 2015 Jul; 33(7):965-71. PubMed ID: 25614256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
